Melanoma: Early Detection and Therapeutic Progress

Similar documents
Melanoma: Therapeutic Progress and the Improvements Continue

Innovations in Immunotherapy - Melanoma. Systemic Therapies October 27, 2018 Charles L. Bane, MD

Current Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology

New paradigms for treating metastatic melanoma

Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy. What every patient needs to know. James Larkin

Approaches To Treating Advanced Melanoma

Immunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital

Treatment and management of advanced melanoma: Paul B. Chapman, MD Melanoma Clinical Director, Melanoma and Immunotherapeutics Service MSKCC

Best Practices in the Treatment and Management of Metastatic Melanoma. Melanoma

Evolving Treatment Strategies in the Management of Metastatic Melanoma: Novel Therapies for Improved Patient Outcomes. Disclosures

Toxicity from Checkpoint Inhibitors. James Larkin FRCP PhD

6/7/16. Melanoma. Updates on immune checkpoint therapies. Molecularly targeted therapies. FDA approval for talimogene laherparepvec (T- VEC)

Melanoma 10/12/18 Justin J. Baker, M.D.

New Therapeutic Approaches to Malignant Melanoma

Metastatic Melanoma. Cynthia Kwong February 16, 2017 SUNY Downstate Medical Center Department of Surgery Grand Rounds

Update on Immunotherapy in Advanced Melanoma. Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017

The Immunotherapy of Oncology

Out of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.

Cancer Progress. The State of Play in Immuno-Oncology

The Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb

New Frontiers in Metastatic Melanoma: A Closer Look at the Role of Immunotherapy

Immunotherapy of Melanoma Sanjiv S. Agarwala, MD

Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania

Update on Melanoma Treatment. Tara C Mitchell, MD

Skin cancer pictures scalp

Priming the Immune System to Kill Cancer and Reverse Tolerance. Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics

IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER

Skin Cancer. 5 Warning Signs. American Osteopathic College of Occupational and Preventive Medicine OMED 2012, San Diego, Monday, October 8, 2012 C-1

III Sessione I risultati clinici

New Systemic Therapies in Advanced Melanoma

Medical Treatment for Melanoma Sanjiv S. Agarwala, MD

Emerging Trends & Strategies in the Treatment & Management of Metastatic Melanoma. Evan J. Lipson, MD

Releasing the Brakes on Tumor Immunity: Immune Checkpoint Blockade Strategies

INIBITORE di BRAF nel MELANOMA

Melanoma. Il parere dell esperto. V. Ferraresi. Divisione di Oncologia Medica 1

WHAT S HOT IN MELANOMA CNS METASTASES?

Summary... 2 MELANOMA AND OTHER SKIN TUMOURS... 3

Immunotherapy Treatment Developments in Medical Oncology

Melanoma in Focus: Update on Novel Therapy, Emerging Agents, and Optimizing Patient Care Presentation 1

Update on Targeted Therapy in Melanoma

Immunotherapy for the Treatment of Cancer

Black is the New Black or How I learned to stop worrying and love melanoma (with apologies to Dr. Strangelove)

Developing Novel Immunotherapeutic Cancer Treatments for Clinical Use

Checkpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health

Melanoma- Fighting the Dark Side

Modern therapy in oncology Metastatic melanoma

Renal Cell Carcinoma: Systemic Therapy Progress and Promise

Locally Advanced and Metastatic Melanoma. Relevant disclosures 6/23/2018. What is the median survival of metastatic melanoma? Abel D.

Enlarge Slides. One Moment Please. Skin Cancer. Thomas Olencki, DO David Carr, MD. Today s Webcast Friday, 09/09/11, Noon

PTAC meeting held on 5 & 6 May (minutes for web publishing)

What You Need to Know about Advanced Melanoma Therapies Targeted Approaches

Immunotherapy for Metastatic Malignant Melanoma. Dr Daniel A Vorobiof Sandton Oncology Centre Johannesburg

Terapia Immunomodulante e Target Therapies nel Trattamento del Melanoma Metastatico

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal (STA) Dabrafenib for treating unresectable, advanced or metastatic

SKIN CANCER AFTER HSCT

One Moment Please. Skin Cancer. Today s Webcast Friday, 09/09/11, Noon. David Carr, MD

Melanoma Clinical Trials and Real World Experience

Melanoma: Immune checkpoints

CheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer

Systemic implications of Melanoma. Melanoma 2/4/2018. Cancer USA Epidemiology: Incidence and Mortality. Skin Cancer USA

Appendices. Appendix A Search terms

MELANOMA: THE BEST OF THE YEAR Dott.ssa Silvia Quadrini UOC Oncologia ASL Frosinone

Hosts. Anees Chagpar, MD Associate Professor of Surgical Oncology. Steven Gore, MD Director of Hematological Malignancies. Melanoma Awareness 2015

Pembrolizumab: First in Class for Treatment of Metastatic Melanoma

ASCO 2014: The Future is Here. What I Will Talk About. George W. Sledge MD Stanford University School of Medicine

Waging War on Skin Cancer and Melanoma

Cancer Immunotherapy Patient Forum. for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015

Corporate Medical Policy

Immune-Related Adverse Events (IRAEs) due to Cancer Immunotherapy

Sentinel Lymph Node Biopsy: Current Evidence for its Role in Managing Melanoma

Current State of Immunotherapy for Metastatic Melanoma

Optimizing Immunotherapy New Approaches, Biomarkers, Sequences and Combinations Immunotherapy in the clinic Melanoma

Immunoterapia e melanoma maligno metastatico: siamo partiti da li. Vanna Chiarion Sileni Istituto Oncologico Veneto

How can we reduce the mortality from melanoma in Australia?

Talking to Your Clients About Skin Cancer. Objectives 9/9/2017. Amanda Friedrichs, MD, FAAD AMTA National Conference September 14, 2017

Role of the Pathologist in Guiding Immuno-oncological Therapies. Scott Rodig MD, PhD

CANCER IMMUNOTHERAPY Presented by John A Keech Jr DO MultiCare Regional Cancer Center

Cancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment

Immunotherapy for Renal Cell Carcinoma. James Larkin

Evan J. Lipson, M.D.

Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016

Dr. Andres Wiernik. Lung Cancer

Novel Therapies in Melanoma the Immunotherapy Approach

IMMUNE CHECKPOINT THERAPY FOR GENITOURINARY CANCERS: KIDNEY CANCER AND TRANSITIONAL CELL CARCINOMA

Immuno-Oncology Applications

Advances in Cancer Immunotherapy for Solid Tumors Expert Perspectives on The New Data Sunday, June 5, 2016

Cancer Registry Report. Cancer Focus: Melanoma

Marshall T Bell Research Resident University of Colorado Grand Rounds Nov. 21, 2011

Advances in Melanoma

Corporate Presentation: Jefferies Global Healthcare Conference June 7, 2018

KEYNOTE 695: TAVO Phase 2b Melanoma Trial Preliminary Data for SITC November 6, 2018

17/01/2017. ckit NRAS BRAF MEK ERK. ANTITUMOR IMMUNE RESPONSE PROLIFERATION

IMMUNOTARGET THERAPY: ASPETTI GENERALI

NCCN Guidelines for Cutaneous Melanoma V Meeting on 06/20/18

2/19/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery

Checkpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015

Lung Cancer Update 2016 BAONS Oncology Care Update

Nuovi approcci immunoterapici nel trattamento del Melanoma: Background immunologico.

Metastasectomy for Melanoma What s the Evidence and When Do We Stop?

2/16/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery

Transcription:

Melanoma: Early Detection and Therapeutic Progress David W. Ollila, MD Professor of Surgery Jesse and James Millis Professor of Surgery Thanks to my collaborators, mentors and patients May 19, 2017 Disclosures: NONE Objectives 1. Skin Cancer Awareness & Education: Importance of early detection 2. To provide an overview of therapeutic progress (2011-2016) Silent National Epidemic The incidence per year is rising faster than any other cancer! For use for educational purposes ONLY. 1

Poorly Regulated Industry NC Law: Illegal for <18 year olds 10-2015 Societal Pressure?» Facebook responses - 1808 Majority against tanning bed For use for educational purposes ONLY. 2

Reality TV Shows? MTV-The Jersey Shore Silent National Epidemic The incidence per year is rising faster than any other cancer! Why Stylists? Early Detection = Better Prognosis For use for educational purposes ONLY. 3

Objectives 1. Skin Cancer Awareness & Education: Importance of early detection 2. To provide an overview of therapeutic progress (2011-2016) Basal Cell Carcinoma ~3.8 million cases in 2017 in US Rarely lethal Preponderance in head and neck region www.skincancer.org Squamous Cell Carcinoma ~ 1 million cases of cutaneous SCC in 2017 in US ~8800 deaths Predominantly sun exposed areas www.skincancer.org For use for educational purposes ONLY. 4

Melanoma 2017 146,280 estimated new cases 87,110 invasive (increasing) 59,170 in situ (increasing) 9,730 deaths (stable) www.skincancer.org Melanoma in situ Cannot spread! Skin Problem ONLY! Invasive Melanoma Can Spread to Lymph Nodes and Vital Organs For use for educational purposes ONLY. 5

Early Detection = Better Prognosis Early Detection = Better Prognosis Early Detection = Better Prognosis Early Detection = Better Prognosis Melanoma Survival ACS 2016 Biopsy??? For use for educational purposes ONLY. 6

Detection of Melanoma A Asymmetry B Border C Color D Diameter E Evolution Rigel DS, Friedman RJ, Kopf AW, Polsky D. Arch Dermatol. 2005 Biopsy??? Detection of Melanoma A Asymmetry B Border C Color D Diameter E Evolution Rigel DS, Friedman RJ, Kopf AW, Polsky D. Arch Dermatol. 2005 For use for educational purposes ONLY. 7

Computer Aided Recognition Computer Aided Recognition Class 2 Device Recall MelaFind FDA May 20, 2015 Take Home Messages Stylists can play a vital role in early detection Identify changing or suspicious lesion Now what?» Suggest evaluation by health care provider: primary care provider or dermatologist Why?» Early detection=better prognosis For use for educational purposes ONLY. 8

Questions?? UNC Dermatology & Skin Cancer Center NC Cancer Hospital Objectives 1. Skin Cancer Awareness & Education: Importance of early detection 2. To provide an overview of therapeutic progress (2011-2016) Melanoma Survival ACS 2016 For use for educational purposes ONLY. 9

Stages IIIbc IV Metastatic Melanoma US FDA Approved Stage IV Systemic Therapy Options Dacarbazine (1970s)» Complete Response 3-5% Interleukin-2 (1998)» Complete Response 7-8% US FDA Approved Stage III Systemic Therapy Options Interferon alpha-2b (1996)» Disease-free but no overall survival advantage Checkpoint Blockade -Inhibiting the Inhibitors PD1 CTLA-4 Pardoll Nat Rev Cancer 2012 For use for educational purposes ONLY. 10

Differences in Checkpoint inhibitors Ribas N Engl J Med 2012 Ipilimumab Prolongs Survival 10.1 vs. 6.4 months, HR 0.66 Hodi et al NEJM 2010 PD-1 Inhibitory Antibodies (BMS936558, MK3475) Topalian N Engl J Med 2012 For use for educational purposes ONLY. 11

Combination Checkpoint Inhibitors Larkin J N Engl J Med. 2015 Jul 2;373(1):23-34 US FDA Approved Stage IV Systemic Therapy Options Ipilimumab (2011)» 10.1 vs. 6.4 months, HR 0.66 Vemurafenib (2011)» 13.6 vs. 9.7 months, HR 0.70 Dabrafenib (2013)» PFS 5.1 vs 2.7 months HR 0.33 Trametinib (2014)» Combination for BRAF mutant US FDA Approved Stage IV Systemic Therapy Options Pembrolizumab (2014)» Response Rate 26% Nivolumab (2014)» RR 40% vs 14% p<0.001» One yr survival 72% vs 42% Combinations.. For use for educational purposes ONLY. 12

US FDA Approved Stage IV Systemic Therapy Options Nivolumab + Ipilimumab (2015)» Untreated Stage IV melanoma» Nivo + Ipi vs Nivo vs Ipi» RR 57% vs 43% vs 19% p<0.001» Median survival not yet published» Side Effects: colitis, diarrhea, pyrexia, pneumonitis Larkin J N Engl J Med. 2015 Jul 2;373(1):23-34 Summary Stylists can make a difference Early detection = Better Prognosis 2011-2016 has seen a dramatic improvement in therapeutic options for metastatic melanoma patients 2017 and beyond. Thank you UNC Dermatology & Skin Cancer Center NC Cancer Hospital For use for educational purposes ONLY. 13

The Role Of The Non Traditional Health Liaison In Early Detection Of Skin Cancer Cosmetologists, Barbers, Estheticians, Nail Care Professionals, Massage Therapists, Personal Trainers, Podiatrists AS (MOSTLY) NON TRADITIONAL HEALTH LIAISONS IN THE COMMUNITY Health Providers and Beauty/Spa Professions have a few things in common State Board Regulated Licensed Scrubs or lab coats For use for educational purposes ONLY. 14

We are natural helpers For use for educational purposes ONLY. 15

Mechanical Flower Connection Confidence Listen For use for educational purposes ONLY. 16

We Observe CONNECT TRUST A CONFIDENCE OBSERVE LISTEN CARE Split Picture TRUSTED PROFFESSIONALS WORKING TOGETHER FOR BETTER HEALTH For use for educational purposes ONLY. 17

SPREAD THE WORD, TELL YOUR SERVICE PROVIDERS TO GET EDUCATED ON HOW TO BECOME A COMMUNITY HEALTH LIASON NOUN A PERSON WHO TOUCHES MORE HEARTS THAN HAIR www. The Flow Beauty Project.com For use for educational purposes ONLY. 18